Mar 20, 2026The FDA stands at a critical crossroads in managing the evolving landscape of individualized therapies for rare diseases. Robert Califf, a former commissioner, underscores how political influence under President Trump seriously compromised the agency's decision-making rigour. Such pressures risk delaying or derailing promising new treatments essential for patients with rare conditions.
Dr. Priya Nandakumar
Mar 19, 2026The evolving political landscape in Washington is prompting Democratic lawmakers to outline a refreshed vision for health care reform. Their agenda seeks to address systemic issues, expand coverage options, and improve affordability in the context of a changing electorate.
Emily Carter
Mar 19, 2026The approval of the high-dose formulation of Wegovy marks a significant milestone both for Novo Nordisk and the FDA’s accelerated review initiatives. This development places Novo alongside notable industry players benefiting from expedited pathway programs designed to quickly deliver critical therapies to patients.
Emily Carter 
Mar 19, 2026As 2026 progresses, the FDA faces both momentum and scrutiny amid dramatic policy shifts affecting biopharma companies. Key issues involve the administration of Regenerative Medicine Advanced Therapy (RMAT) awards and challenges surrounding priority review vouchers, which have historically incentivized innovation but are now being questioned.
Dr. Priya Nandakumar 
Mar 19, 2026The FDA faces a critical transition as Adam Sherwat, a leading figure in infectious disease regulation, steps down. His tenure oversaw key drug evaluations during a complex era marked by global epidemics and advancing therapies.
Emily Carter 
Mar 18, 2026The U.S. Department of Health and Human Services (HHS) is placing increasing emphasis on reducing the reliance on animal testing within pharmaceutical research and development. The FDA and NIH are coordinating new strategies and funding mechanisms designed to promote innovative testing methods that could replace traditional animal-based experiments.
Michael Torres
Mar 17, 2026At SXSW, observers detailed the uneven return to stability within the Food and Drug Administration, highlighting which divisions are most secure. Additionally, the gradual integration of AI tools across the FDA's departments exemplifies a broader institutional shift towards technological adoption aimed at improving regulatory processes and decision-making speed.
Jonathan Blake
Mar 17, 2026Recent developments in the Epic-Health Gorilla lawsuit reveal serious concerns about data privacy in healthcare interoperability networks. GuardDog Telehealth's admission marks a critical juncture, raising questions about the safeguards in place to protect patient information as providers and tech firms navigate complex data-sharing ecosystems.
Michael Torres 
Mar 16, 2026Robert F. Kennedy Jr., serving as Health Secretary, has generated significant controversy with his antivaccine stance and related policy decisions. As the political landscape heats up ahead of the midterms, the federal government seeks to counter and regulate these policies, raising questions about public health strategy and government cohesion.
Jonathan Blake 
Mar 15, 2026The U.S. Food and Drug Administration (FDA) has granted approval for leucovorin as a treatment for cerebral folate deficiency, marking a historic moment for this rare disease. This decision came months after comments by FDA Commissioner Marty Makary about the drug's promise for autism treatment, a claim that the current approval does not support.
Dr. Alex Morgan
Mar 14, 2026This recent cyberattack on Stryker, a major global medical device manufacturer, exposed vulnerabilities in healthcare cybersecurity. The attack caused widespread operational delays, affecting supply chains and posing risks to patient care delivery. Here are six essential points to understand the incident, its implications, and the broader lessons for healthcare organizations.
Dr. Priya Nandakumar 
Mar 13, 2026In a significant shift in cardiovascular health strategy, cardiology groups have updated guidelines recommending adults from age 30 begin assessing their cholesterol risk. This recommendation could lead to earlier preventative treatments, potentially reducing the long-term incidence of heart disease and stroke.
Dr. Alex Morgan 